Bioline Rx Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Monitoring Framework
Key Performance Indicators
APHEXDA Royalty Revenues Quarterly477K
Cash and Cash Equivalents Quarterly17.4MTarget: Sufficient to fund operations into the first half of 2027
Research and Development Expenses Quarterly2.5M
Watch Items
- GLIX1 Phase 1/2a Clinical Trial ProgressTrigger: Periodic updates in H2 2026; full dose-escalation results in 2027Action: Monitor safety, PK/PD, and preliminary efficacy data to establish recommended Phase 2 dose
- CheMo4METPANC Phase 2b Clinical Trial Interim AnalysisTrigger: Observation of 40% of progression-free survival (PFS) eventsAction: Evaluate futility/efficacy readout expected in 2026 for motixafortide in metastatic pancreatic cancer
- Ayrmid Commercialization of APHEXDATrigger: Quarterly royalty revenue growthAction: Track global sales performance (excluding Asia) to assess non-dilutive cash flow contribution
Research as of 20 Jun 2026